RxDoctor Payments Data

Steven Steinlauf, MD

Orthopaedic Surgery · Hollywood, FLNPI 1528050143

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.1%), royalties or licence payments and speaking fees — rather than concentrated in one kind of arrangement. Stryker accounts for 63.4% of it on its own, with 16 other manufacturers making up the rest. Among orthopaedic surgery clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$671,041in general payments, 2019–2025

Across 435 payments — averaging $1542.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$425K
  • Smith+Nephew$194K
  • Tyber Medical, LLC$35K
  • DJO, LLC$8K
  • Extremity Medical$6K
  • Zimmer Biomet$2K
  • plus $1K from 11 others
$40,008in research payments, 2019–2025

Across 65 payments — averaging $615.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • DJO, LLC$26K
  • Stryker$14K

What the payments were for

  • Royalty or licence$243,94436%
  • Consulting fees$288,91543%
  • Speaking & faculty fees$103,65915%
  • Travel & lodging$26,6154%
  • Food & beverage$7,4521%
  • Education$4560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$671,041 in reported general payments places this provider in the 95th percentile of 1,263 orthopaedic surgery providers in Florida.

See all orthopaedic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$94,385
Medicare patients
241
Services billed
698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban13$6,644
Naloxone Hcl16$941
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen26$341
Ondansetron Hcl36$190
Gabapentin17$178
Tramadol Hcl15$46
Meloxicam11$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$122$6,64413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,263 orthopaedic surgery providers in Florida.

Other orthopaedic surgery in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →